78081-87-5

Basic information

• Product Name: FMOC-LYS(FMOC)-OH
• Synonyms: Fmoc-Lys(Fmoc)-OH >=98.0% (HPLC);Nα,Nε-Bis[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysine;Nα,ε-Bis-Fmoc-L-lysine≥ 99.7% (HPLC, Chiral purity);N-2-N-6-BIS-FMOC-L-LYSINE;N,N-BIS-FMOC-L-LYSINE;N-ALPHA,E-DI-FMOC-L-LYSINE;N-ALPHA,EPSILON-BIS-FMOC-L-LYSINE;N-ALPHA,EPSILON-DI-FMOC-L-LYSINE
• CAS NO: 78081-87-5
• Molecular Formula: C₃₆H₃₄N₂O₆
• Molecular Weight: 590.66
• Product Categories: pharmacetical;Amino Acids;Lysine [Lys, K];Fmoc-Amino Acids and Derivatives;Fmoc-Amino acid series
• Mol File: 78081-87-5.mol
• Article Data: 5

Chemical Properties

• Melting Point: 120-130°C
• Boiling Point: 835.2 °C at 760 mmHg
• Flash Point: 458.9 °C
• Appearance: /
• Density: 1.278 g/cm³
• Vapor Pressure: 1.36E-29mmHg at 25°C
• Refractive Index: 1.629
• Storage Temp.: 2-8°C
• PKA: 3.88±0.21(Predicted)
• BRN: 6034060
• CAS DataBase Reference: FMOC-LYS(FMOC)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-LYS(FMOC)-OH(78081-87-5)
• EPA Substance Registry System: FMOC-LYS(FMOC)-OH(78081-87-5)

Safety Data

• WGK Germany: 3
• F: 10
• Hazardous Substances Data: 78081-87-5(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

Different sources of media describe the Uses of 78081-87-5 differently. You can refer to the following data:
1. Fmoc-Lys(Fmoc)-OH is useful derivative for the synthesis of branched peptides.
2. Fmoc-Lys(Fmoc)-OH is used in the synthesis of [Lys8]-oxytocin related dendrimer which were functionally active in vitro on human oxytocin receptors and inhibited colonic nociceptors potently in a mouse model of chronic abdominal pain.

InChI:InChI=1/C36H34N2O6/c39-34(40)33(38-36(42)44-22-32-29-17-7-3-13-25(29)26-14-4-8-18-30(26)32)19-9-10-20-37-35(41)43-21-31-27-15-5-1-11-23(27)24-12-2-6-16-28(24)31/h1-8,11-18,31-33H,9-10,19-22H2,(H,37,41)(H,38,42)(H,39,40)/t33-/m0/s1

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 
• 56-87-1 L-lysine 
• 657-27-2 L-Lysine hydrochloride 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 

Downstream Products

• 439286-58-5 (S)-2,6-Diamino-hexanoic acid {2-[2-(2,4-dichloro-phenoxy)-acetylamino]-ethyl}-amide 
• 389117-95-7 N^α,N^ε-Bis-[(3R,4S,5R)-3,4,5-trihydroxycyclohexanecarbonyl]-L-lysyl-L-cysteinyl-glycine 
• 1433960-38-3 Ac-CGVQIVYKK-NH₂ 

Relevant articles and documents

Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin

Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy. It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans. Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies. The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain. The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac. In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation. Moreover, compound 45 rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease. This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.

ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

Studies on peptides. CLX. Synthesis of a 33-residue peptide corresponding to the entire amino acid sequence of human cholecystokinin (hCCK-33)

-